, 40:B89 | Cite as

New insulins and other possible therapeutic approaches

  • J. Johannesen
  • K. F. Petersen
  • M. Berger
  • C. Binder


Insulin Lispro Regular Insulin Pramlintide Short Acting Insulin Fructosamine Concentration 


  1. 1.
    Zinman B, Tildesley H, Chiasson JH, Tsui E, Strack T (1997) Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 46: 440–443CrossRefPubMedGoogle Scholar
  2. 2.
    Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312: 71–72PubMedGoogle Scholar
  3. 3.
    Young AA, Wang MW, Gedulin B, Rink TJ, Pittner R, Beaumont K (1995) Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism 44: 1581–1589CrossRefPubMedGoogle Scholar
  4. 4.
    Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A (1996) Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC 137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39: 492–499CrossRefPubMedGoogle Scholar
  5. 5.
    Thompson RG, Pearson L, Gottlieb A, Kolterman OG (1996) Pramlintide, an analog of human amylin, reduced fructosamine in patients with type 1 diabetes. Diabetes 45: [Suppl 2] 222A (Abstract)Google Scholar
  6. 6.
    Wahren J, Johansson B-L, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath J R (1996) C-peptide revisited — new physiological effects and therapeutic implications. J Int Med 240: 115–124CrossRefGoogle Scholar
  7. 7.
    Zenobi PD, Glatz Y, Keller A et al. (1994) Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin resistant diabetes type A. Eur J Endocrinol 131: 251–257CrossRefPubMedGoogle Scholar
  8. 8.
    Dunger DB, Cheetham TD, Crowne EC (1995) Insulin growth factors (IGFs) and IGFI treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 44: 119–123CrossRefPubMedGoogle Scholar
  9. 9.
    Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR (1996) Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes 45: 91–100CrossRefPubMedGoogle Scholar
  10. 10.
    Mitragotri S, Blankschtein D, Langer R (1995) Ultrasound-mediated transdermal protein delivery. Science 269: 850–853CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • J. Johannesen
    • 1
  • K. F. Petersen
    • 2
  • M. Berger
    • 3
  • C. Binder
    • 1
  1. 1.Steno Diabetes CenterGentofteDenmark
  2. 2.Department of Internal MedicineYale University School of MedicineNew HavenUSA
  3. 3.Heinrich Heine UniversitätDüsseldorfGermany

Personalised recommendations